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Abstract
Background: Equine parvovirus- hepatitis (EqPV- H) research is in its infancy. 
Information regarding prevalence, geographical distribution, genetic diversity, patho-
genesis and risk factors enhances understanding of this potentially fatal infection.
Objectives: Determining the prevalence of EqPV- H in Austrian equids. Investigating 
factors increasing probability of infection, liver- associated biochemistry parameters, 
concurrent equine hepacivirus (EqHV) infection and phylogenetic analysis of Austrian 
EqPV- H variants.
Study design: Cross- sectional study.
Methods: Sera from 259 horses and 13 donkeys in Austria were analysed for anti- 
EqPV- H VP1- specific antibodies by luciferase immunoprecipitation system (LIPS) 
and EqPV- H DNA by nested polymerase chain reaction (PCR). Associations between 
infection status, sex and age were described. Glutamate dehydrogenase (GLDH), 
gamma- glutamyl transferase (GGT), bile acids and albumin concentrations were com-
pared between horses with active infection and PCR- negative horses. PCR targeting 
partial EqPV- H NS1 was performed and phylogenetic analysis of Austrian EqPV- H 
variants was conducted. Complete coding sequences (CDS) of four Austrian variants 
were determined by next- generation sequencing (NGS) and compared with published 
sequences.
Results: Horses' EqPV- H seroprevalence was 30.1% and DNA prevalence was 
8.9%. One horse was co- infected with EqHV. Significantly, higher probability of ac-
tive EqPV- H infection was identified in 16- to 31- year- old horses, compared with 
1- to 8- year- old horses (P = 0.002; OR = 8.19; 95% CI = 1.79 to 37.50) and 9- to 
15- year- old horses (P = 0.03; OR = 2.96; 95% CI = 1.08 to 8.17). Liver- associated 
plasma parameters were not significantly different between horses with active in-
fection and controls. Austrian EqPV- H variants revealed high similarity to sequences 
worldwide. No evidence of EqPV- H was detected in donkeys.
Main limitations: Equids’ inclusion depended upon owner consent. There was only 
one sampling point per animal and the sample of donkeys was small.
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1  | INTRODUC TION
Equine parvovirus- hepatitis (EqPV- H) was first detected in 2018 in a 
case of fatal equine serum hepatitis in the USA.1 EqPV- H and equine 
hepacivirus (EqHV) are currently regarded as the two most clinically 
relevant viral agents associated with equine hepatitis.2 Since the initial 
report, significant progress has been made in demonstrating the hepa-
totropism of EqPV- H and its association with equine serum hepatitis— 
also known as Theiler's disease— despite the lack of a pure, clonal, 
EqPV- H inoculum to confirm disease causation.1,3– 7 Furthermore, 
EqPV- H has also frequently been detected in horses with subclinical 
hepatitis.5,6,8 Surveillance studies in apparently healthy horse popula-
tions in the USA, China and Germany have demonstrated that EqPV- H 
DNA prevalence ranges between 7.14% and 17%,1,8– 11 and seropreva-
lence ranges between 15% and 34.7%.1,11 Age and breeding history are 
speculated to be risk factors associated with EqPV- H infection, while 
seasonal occurrence of EqPV- H- associated cases of clinical hepatitis 
has been reported.4,6,11 EqPV- H was recently allocated the species 
name Ungulate copiparvovirus 6.12 It is one of three parvoviruses known 
to infect horses, all of which are members of the Copiparvovirus genus 
of the family Parvoviridae.1,10,13 Apart from a single recombination event 
between Chinese and American EqPV- H strains, low genetic diversity 
has been reported among EqPV- H variants identified globally.1,5,8,9,11,14
Research pertaining to EqPV- H is at an early, critical stage. Data 
regarding prevalence, geographical distribution, genetic diversity, 
pathogenesis and associated risk factors are essential to enhance 
our understanding of this potentially fatal infection. This information 
will form the basis of future control and prevention strategies. In this 
first report of EqPV- H in Austrian equids, molecular and serological 
evidence of active or prior infection was investigated in 259 horses 
and 13 donkeys. Furthermore, investigation of concurrent EqHV in-
fection, changes in liver- associated plasma biochemistry parameters, 
factors increasing probability of infection and phylogenetic analysis 
of Austrian EqPV- H variants were performed.
2  | MATERIAL S AND METHODS
2.1 | Study design and population
In this cross- sectional study, serum and plasma samples were 
collected for surveillance purposes from 259 horses and 13 
donkeys in eastern Austria between July and October 2017. 
Sampled equids included the teaching horses of the University of 
Veterinary Medicine Vienna (Vetmeduni) (n = 50) and privately 
owned, clinically unremarkable horses (n = 209), and donkeys 
(n = 13) enrolled voluntarily. The horse sample population con-
sisted of various breeds and included 112 mares, 107 geldings, 39 
stallions and one horse with the sex undisclosed. The horses’ ages 
ranged from 1 to 31 years (median age = 11.92 years). The ages 
of three horses were unknown. The geographic coordinates of 
the horses’ properties of origin were recorded and plotted using 
Google Maps.
Considering an approximated population of 120 000 horses 
in Austria, an appropriate sample size was estimated. The ex-
pected prevalence of horses positive for EqPV- H DNA was set to 
11.5%— the average DNA prevalence of five surveillance studies 
in apparently healthy horse populations of various breeds and 
ages, conducted in the USA (DNA prevalence figures = 13% and 
17%),1,10 China (DNA prevalence figures = 11.9% and 8.33%)8,9 and 
Germany (DNA prevalence = 7.14%)11 respectively. Given a con-
fidence level of 95%, a sample size of 157 horses was required. 
The expected prevalence of EqPV- H antibody- positive horses was 
set to 24.9%— the average antibody prevalence of two surveillance 
studies in apparently healthy horse populations of various breeds 
and ages, performed in the USA (antibody prevalence = 15%)1 and 
Germany (antibody prevalence = 34.7%)11 respectively. Given a 
confidence level of 95%, a sample size of 288 horses was required. 
Hence, the investigation of 259 horses was considered sufficient 
to estimate the prevalence of EqPV- H DNA and antibodies in 
Austrian horses. Sample size calculations were performed using 
Epitools Ausvet.15
Data collection was approved by the Ethics Committee of the 
University of Veterinary Medicine Vienna and the Austrian Federal 
Ministry of Education, Science and Research (study reference num-
ber BMWF- 68.205/0125- WF/V/3b/2017). Informed, written con-
sent for participation in the study was obtained from the individual 
equid owners and managers.
2.2 | Laboratory analysis
Serum samples were frozen between −20°C and −80°C prior to 
analysis.
Conclusions: EqPV- H antibodies and DNA are frequently detected in Austrian horses, 
without associated hepatitis in horses with active infection. The risk of active EqPV- H 
infection increases with increasing age. Phylogenetic evidence supports close relation 
of EqPV- H variants globally, including Austrian variants.
K E Y W O R D S
horse, liver, luciferase immunoprecipitation system, nested polymerase chain reaction, next- 
generation sequencing, ungulate copiparvovirus 6
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2.2.1 | Detection of anti- EqPV- H VP1- specific 
antibodies in serum
Serum was shipped on dry ice to the laboratory in Germany for 
detection of anti- EqPV- H capsid protein VP1- specific antibod-
ies. Samples were analysed in duplicate for the presence of anti- 
EqPV- H VP1 antibodies using a luciferase immunoprecipitation 
system (LIPS) as described previously.1,16,17 The VP1 antigen for 
the EqPV- H LIPS was produced as described previously.1 Relative 
light units (RLUs) were measured with a plate luminometer (LB 960 
XS3; Berthold). The threshold value, above which samples were re-
garded as antibody- positive, was calculated for each plate using the 
RLU value plus three standard deviations (SD) of EqPV- H- negative 
horse serum.
2.2.2 | Detection of EqPV- H DNA and EqHV RNA 
in serum
Two hundred microliters of serum were used for nucleic acid extrac-
tion. Extraction was performed with a QIAcube HT instrument using 
the QIAamp 96 Virus QIAcube HT Kit (Qiagen) according to the man-
ufacturer's instructions. Negative controls consisted of sample- free 
extracts (blanks) and were processed simultaneously in each extrac-
tion round.
EqPV- H- specific sequences were detected with a nested PCR 
using two primer pairs targeting the NS gene, which were published 
previously.1 Both PCRs were carried out in a reaction volume of 
20 µL using the Fast Cycling PCR Kit (Qiagen, Hilden, Germany) 
according to the manufacturer's guidelines. In short, after an ini-
tial step of 95°C for 5 minutes, the PCRs were run for 45 cycles 
of denaturation at 96°C for 5 seconds, primer annealing at 60°C 
for 5 seconds and primer extension at 68°C for 15 seconds. The 
PCR was finalised by an ultimate extension of 1 minute at 72°C. 
To ensure validity of the assays, positive and negative controls 
(blanks) were run in parallel with each PCR reaction. Finally, the 
PCR products were analysed using a capillary electrophoresis de-
vice, QIAxcel Advanced System (Qiagen, Hilden, Germany). The 
limit of detection of this nested PCR was determined by running 
duplicates of a 10- fold dilution row of a plasmid containing the tar-
get sequence and was determined to be 3 x 10^3 genome equiva-
lents (GE)/ml horse serum.
EqHV- specific sequences were detected in serum samples by 
reverse transcription quantitative PCR (RT- qPCR) as described 
previously.18
2.2.3 | Plasma biochemistry
Plasma samples were analysed for glutamate dehydrogenase (GLDH), 
gamma- glutamyl transferase (GGT), bile acids and albumin concen-
trations. These parameters were measured in plasma samples of all 
horses with active EqPV- H infection ([Ab+/DNA+] + [Ab−/DNA+]), 
as well as in plasma samples of control horses (n = 45). The control 
horses were randomly selected from archived samples of clinically 
unremarkable horses that were known to be both EqPV- H and EqHV 
PCR- negative. The reference ranges of the Central Laboratory, 
Vetmeduni Vienna were used for data analysis.
2.3 | Data analysis
Herd prevalence (the % of properties with at least one horse in a 
particular infection status category) and inner- herd prevalence (the 
average % of horses in a particular infection status category per 
property) were calculated for the various EqPV- H infection status 
categories, to avoid overestimation of prevalence due to inclusion of 
properties with low numbers of horses.
For all statistical analyses based on sex, horses were grouped as 
males (n = 146; 107 geldings and 39 stallions) and females (n = 112). 
Horses with no evidence of EqPV- H infection [Ab−/DNA−] were 
compared with horses with evidence of active or prior EqPV- H in-
fection ([Ab+/DNA−] + [Ab+/DNA+] + [Ab−/DNA+]). For all statis-
tical analyses based on age, groups of similar size were created: 1- to 
8- year- old horses (n = 80), 9- to 15- year- old horses (n = 87) and 16- 
to 31- year- old horses (n = 89). Horses with no evidence of EqPV- H 
infection [Ab−/DNA−] were compared with horses with evidence of 
active EqPV- H infection ([Ab+/DNA+] + [Ab−/DNA+]). For statisti-
cal analysis based on age, horses with evidence only of prior EqPV- H 
infection [Ab+/DNA−] were excluded, because information about 
the exact age at the time of EqPV- H infection in these individuals 
was not available.
Chi- square tests were performed to analyse the difference in 
the frequency distribution of horses with and without evidence 
of infection (as defined in the previous paragraph) between dif-
ferent sexes and different age groups. Subsequently, the odds 
ratio (OR), the confidence interval (CI) of the OR and the p- value 
was determined for pairwise comparisons of horses with and 
without evidence of infection, between different sexes and dif-
ferent age groups. Finally, logistic regression was performed to 
analyse the impact of age and sex on the probability of being 
infected (as defined above), where both predictors, age and sex, 
were included in the first model. In a second model, only age was 
included.
For statistical analysis of liver- associated plasma biochemistry 
parameters, results of horses with evidence of active EqPV- H in-
fection ([Ab+/DNA+] + [Ab−/DNA+]) were compared with results 
of control horses that were known to be both EqPV- H and EqHV 
PCR- negative. Plasma biochemistry results were assessed for 
normality using the Shapiro- Wilk test. The Mann- Whitney U test 
was used for nonparametric testing when the dependent variable 
(plasma biochemistry parameter) was not normally distributed for 
at least one category of the independent variable (EqPV- H DNA 
status). A P- value ≤ .05 was considered statistically significant for 
all analyses. Statistical analysis was performed using IBM SPSS 
Statistics v24.
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2.4 | Sequencing and phylogenetic analyses
A PCR targeting partial NS1 of EqPV- H was performed, as previously 
published by Meister et al., prior to analysis of EqPV- H sequences 
of Austrian horses.11 Only reliable sequences were used for further 
analysis and uploaded to NCBI (accession numbers MT559076 to 
MT559081). Published sequences were downloaded from https://
www.ncbi.nlm.nih.gov/nucle otide/ in April 2020. Sequences were 
aligned with MUSCLE and ClustalW in MEGA 7 and trimmed to 
partial NS1 sequence length of PCR products. Maximum likelihood 
phylogeny was performed with 500 bootstraps in MEGA 719 and 
the general time- reversible model20 was applied. A discrete gamma 
distribution was used to model evolutionary rate differences 
among sites (six categories). Gaps and missing data were com-
pletely deleted. The analysis involved 50 sequences in total, with 
478 nucleotide positions in the final dataset. A phylogenetic tree 
was drawn to scale, with branch lengths measured in the number 
of substitutions per site. The tree with the highest log likelihood 
(−1845.41) is shown.
To obtain full genomes of EqPV- H, a standard metagenomic 
next- generation sequencing (NGS) approach was used.21 RNA and 
DNA were extracted from serum using the QIAamp Viral RNA mini 
kit (Qiagen). Subsequently, the RNA was transcribed and the sec-
ond strand was synthesised and amplified by sequence- independent 
single primer amplification, as previously described.22,23 Sequencing 
libraries were prepared from amplified DNA using the NEBNext 
Ultra II DNA library prep kit and the NEBNext® Multiplex Oligos 
for Illumina® (96 Unique Dual Index Primer Pairs) (both New 
England Biolabs, Ipswich, MA, USA), and sequenced on the Illumina 
NovaSeq system in a paired- end 2 × 150 nucleotide (nt) run at the 
Functional Genomics Center Zurich (FGCZ). After technical quality 
control, the generated reads were de novo assembled using mega-
hit (version 1.1.3) with multiple k- mers and annotated by BLASTN 
(version 2.6.0+) to the NCBI nt database. The two open reading 
frames (ORFs) of the assembled sequences were determined using 
Clone Manager 9 Professional (SciEd software). Four genomes with 
complete ORFs for NS1 and VP were generated and deposited in 
GenBank (accession numbers MW256660 to MW256663). For phy-
logenetic analysis using MEGA X,24 all 12 available complete coding 
sequences (CDS) of representatives of the species Ungulate copipar-
vovirus 6 (Genbank, November 2020) as well as one representative 
of the other six species of the genus Copiparvovirus were included 
in a maximum likelihood tree with 1000 bootstraps. The sequence 
length was 4725 nt for all members of the species Ungulate copipar-
vovirus 6 and ranged between 5011 and 5566 nt for members of the 
other species. Taxonomy is based on the current status published 
by the International Committee on Taxonomy of Viruses (ICTV, 
November 2020).
3  | RESULTS
3.1 | Evidence of active or prior equine parvovirus- 
hepatitis infection is frequently detected in Austrian 
horses
In this study, serum samples from Austrian horses (n = 259) and 
donkeys (n = 13) were analysed for serological and molecular evi-
dence of active or prior EqPV- H infection. The samples originated 
from 21 properties in eastern Austria (Figure 1A and B). The EqPV- H 
antibody prevalence among horses was 30.1%, with 78 of 259 sam-
ples antibody- positive. The EqPV- H DNA prevalence among horses 
was 8.9%, with 23 of 259 samples DNA- positive. The samples could 
be assigned to four categories based on the horses’ EqPV- H anti-
body status and DNA status: antibody- negative and DNA- negative 
[Ab−/DNA−]; antibody- positive and DNA- negative [Ab+/DNA−]; 
antibody- positive and DNA- positive [Ab+/DNA+] and antibody- 
negative and DNA- positive [Ab−/DNA+] (Figure 2A and B). One 
hundred and seventy- nine samples (69.1%) tested negative for both 
F I G U R E  1   (A) Geographical locations of horse and donkey 
properties of origin in Austria. Serum samples from 259 horses and 
13 donkeys were analysed for serological and molecular evidence 
of active or prior EqPV- H infection. (B) The samples originated 
from 21 properties, the locations of which are indicated on this 
magnified map of eastern Austria. Magenta horse icons (n = 17) 
represent properties with evidence of active and/or prior EqPV- H 
infections ([Ab+/DNA−] and/or [Ab+/DNA+] and/or [Ab−/DNA+]) 
in collected serum samples. Black horse icons (n = 4) represent 
properties with no evidence of active or prior EqPV- H infection 
[Ab−/DNA−] in collected serum samples
(B)
(A)
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EqPV- H antibodies and DNA. Fifty- seven samples (22%) contained 
only antibodies but no DNA. Twenty- one samples (8.1%) contained 
both antibodies and DNA. Two samples (0.8%) contained only DNA 
but no antibodies, indicating acute infection. Only 1/23 (4.3%) of the 
EqPV- H DNA- positive horses was found to be EqHV RNA- positive 
as well. No EqPV- H antibodies or DNA were detected in the donkey 
serum samples.
3.2 | EqPV- H infection status and the 
property of origin, sex and age of horses
The number of horses sampled per property varied from 1 to 45 
(Table 1). Evidence of active and/or prior EqPV- H infection ([Ab+/
DNA−] and/or [Ab+/DNA+] and/or [Ab−/DNA+]) was detected 
in samples which originated from 17/21 (81%) of the properties 
(Table 1). Herd prevalence and inner- herd prevalence results are re-
ported in Table 2.
The proportions of mares, geldings and stallions allocated 
to each of the four EqPV- H infection status categories are illus-
trated in Figure 3A. Age groups of similar size were created: 1- to 
8- year- old horses (n = 80), 9- to 15- year- old horses (n = 87) and 16- 
to 31- year- old horses (n = 89). The proportions of horses in each age 
group allocated to each of the four EqPV- H infection status catego-
ries are illustrated in Figure 3B.
The Chi- square test indicated no statistically significant difference 
between males and females in frequency distribution of horses with 
and without evidence of infection, as defined in the Materials and 
Methods (X2(1) = 1.4; P = .242). Both of the acutely infected horses 
[Ab−/DNA+] were female, aged 6 years and 25 years respectively. 
The Chi- square test did, however, indicate statistically significant 
difference between age groups in frequency distribution of horses 
with and without evidence of infection, as defined in the Materials 
and Methods (X2(2) = 11.7; P = .003). Subsequent pairwise analysis 
identified a significantly higher chance of EqPV- H infection in 16- to 
31- year- old horses, compared with 1- to 8- year- old horses (P = .002; 
OR = 8.19; 95% CI of OR = 1.79 to 37.50), as well as 9- to 15- year- old 
horses (P = .03; OR = 2.96; 95% CI of OR = 1.08 to 8.17) (Table 3).
The first logistic regression model found no significant impact 
of age (P = .8; OR = 1.02; 95% CI of OR = 0.83 to 1.25), sex (P = .3; 
OR = 0.22; 95% CI of OR = 0.02 to 3.03) or the interaction of these 
predictors (P = .5; OR = 1.05; 95% CI of OR = 0.91 to 1.22) on the 
probability of being infected. In the second model, using only age as a 
predictor, age becomes significant (intercept = −3.44; slope = 0.096; 
P = .005; OR = 1.1; 95% CI of OR = 1.03 to 1.18) (Figure 4A). The 
probability of active infection according to age group is illustrated 
in Figure 4B.
3.3 | Plasma biochemistry
Mildly increased GGT levels (GGT = 37 U/L; reference < 30 U/L) 
were detected in two horses with active EqPV- H infection. One 
of these two horses was acutely infected [Ab−/DNA+]. All other 
plasma biochemistry parameters investigated in the horses with ac-
tive EqPV- H infection ([Ab+/DNA+] + [Ab−/DNA+]) (n = 23) were 
within laboratory reference ranges. Comparison of GLDH, GGT, bile 
acids and albumin levels between horses with active EqPV- H infec-
tion (n = 23) and control horses (n = 45) revealed no statistically sig-
nificant differences (Table 4, Figure 5). Control horses were known 
to be both EqPV- H and EqHV PCR- negative. All four parameters 
were within laboratory reference ranges in the plasma of the horse 
co- infected with EqPV- H and EqHV.
3.4 | Sequence and phylogenetic analyses
To gain a better understanding of the variability of EqPV- H 
variants circulating in Austria compared with other parts of the 
world, we conducted phylogenetic analysis based on partial NS1 
sequences (Figure 6) for six variants, as well as the complete 
F I G U R E  2   Prevalence of EqPV- H antibodies and DNA 
in 259 Austrian horses. (A) The log- transformed luciferase 
immunoprecipitation system (LIPS) value in relative light units 
(RLUs) for each of the horses. The threshold between antibody- 
positive and - negative is represented by the dashed line. EqPV- H 
DNA- positive horses (n = 23) are indicated in red and EqPV- H 
DNA- negative horses are indicated in black. (B) Horses were 
divided into four categories, based on their EqPV- H antibody 
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CDS (Figure 7) for four variants. In the overlapping NS1 coding 
region, the sequences generated by amplicon sequencing and 
metagenomic NGS were identical, confirming correctness of 
the sequences. The corresponding accession numbers for the 
partial NS1 sequence and complete CDS of these four variants 
are: MT559076 and MW256660; MT559078 and MW256661; 
MT559079 and MW256662; MT559080 and MW256663. As 
expected, the overall differences at nucleotide level were minor. 
In the NS1 region, sequences originating from Austrian horses 
showed high similarity to previously published sequences from 
Germany, Italy and China (Figure 6). For the comparison of the 
complete CDS, only sequences from China and the type strain 
from the USA were available and these were closely related to the 
Austrian sequences (Figure 7).








n % n % n % n %
A 13 11 84.6 0 0 2 15.4 0 0
B 7 2 28.6 3 42.9 2 28.6 0 0
C 10 8 80 2 20 0 0 0 0
D 19 17 89.5 1 5.3 1 5.3 0 0
E 12 7 58.3 3 25 2 16.7 0 0
F 15 12 80 2 13.3 1 6.7 0 0
G 1 0 0 0 0 1 100 0 0
H 3 2 66.7 1 33.3 0 0 0 0
I 17 8 47.1 6 35.3 2 11.8 1 5.9
J 14 13 92.9 1 7.1 0 0 0 0
K 31 24 77.4 3 9.7 3 9.7 1 3.2
L 1 1 100 0 0 0 0 0 0
M 19 12 63.2 4 21.1 3 15.8 0 0
N 7 1 14.3 5 71.4 1 14.3 0 0
O 10 9 90 1 10 0 0 0 0
P 2 2 100 0 0 0 0 0 0
Q 12 4 33.3 8 66.7 0 0 0 0
R 4 4 100 0 0 0 0 0 0
S 12 9 75 2 16.7 1 8.3 0 0
T 45 28 62.2 15 33.3 2 4.4 0 0
U 5 5 100 0 0 0 0 0 0
Total 259 179 69.1 57 22 21 8.1 2 0.8
Abbreviation: Ab, antibodies.
TA B L E  1   Number of horses sampled 
and their corresponding EqPV- H infection 
status, according to the property of origin 
(n = 21)








Inner- herd prevalenced  9.6% 11.3% 0.4%
Interquartile range 0- 33.3 0- 14.9 - - 
Abbreviation: Ab, antibodies.
aProperties with at least one [Ab+/DNA−] horse. 
bProperties with at least one [Ab+/DNA+] horse. 
cProperties with at least one [Ab−/DNA+] horse. 
dAverage % of horses in this category per property. 
TA B L E  2   Herd prevalence and inner- 
herd prevalence of the various EqPV- H 
infection status categories
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4  | DISCUSSION
Both the EqPV- H seroprevalence and DNA prevalence detected 
in this population of apparently healthy Austrian horses of various 
breeds and ages fall within the ranges published for surveillance 
studies of other clinically healthy populations worldwide.1,8– 11 The 
route of infection in the two cases of acute infection remains spec-
ulative, as information regarding recent administration of biological 
products was not available for these horses. Parenteral inoculation 
with virus- containing biological products of equine origin as well as 
a single case of enteral inoculation with EqPV- H- positive serum are 
currently the only confirmed routes of horizontal EqPV- H transmis-
sion.1,6 Despite several reports of EqPV- H/EqHV co- infection, with 
F I G U R E  3   Bar graphs illustrating the proportions of horses in 
each of the four categories of EqPV- H infection status, according to 































TA B L E  3   The odds ratio (OR), the confidence interval (CI) of 
the OR and the p- value for pairwise comparisons of horses with 
and without evidence of infection, between different sexes and 
different age groups. For statistical analysis based on sex, horses 
with no evidence of EqPV- H infection [Ab−/DNA−] were compared 
with horses with evidence of active or prior EqPV- H infection 
([Ab+/DNA−] + [Ab+/DNA+] + [Ab−/DNA+]). For statistical 
analysis based on age, horses with no evidence of EqPV- H infection 
[Ab−/DNA−] were compared with horses with evidence of active 
EqPV- H infection ([Ab+/DNA+] + [Ab−/DNA+]). For statistical 
analysis based on age, horses with evidence only of prior EqPV- H 
infection [Ab+/DNA−] were excluded, because information about 
the exact age at the time of EqPV- H infection in these individuals 
was not available
Comparison P- value OR






Male vs female 0.2 1.38 0.80 2.37
Age
9- to 15- year- olds vs 
1- to 8- year- olds
0.2 2.77 0.54 14.24
16- to 31- year- olds vs 
9- to 15- year- olds
0.03* 2.96 1.08 8.17
16- to 31- year- olds vs 
1- to 8- year- olds
0.002* 8.19 1.79 37.50
*P ≤ .05 was considered statistically significant. 
F I G U R E  4   (A) Probability (p) of being infected according to 
age (in years) as a result of the second logistic regression model. 
(B) A box and whisker plot illustrating the probability (p) of 
active infection for the age groups 1 to 8 years (mean = 5.3%; 
standard error of mean/SEM = 0.1%), 9 to 15 years (mean = 9.2%; 
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or without clinical disease,1,3,8,9,25,26 Meister et al. concluded that 
EqHV infection does not predispose horses to EqPV- H infection.11 
Evidence of EqPV- H transmission to other equid species has not 
yet been reported and EqPV- H antibodies and DNA were absent 
from the small number of donkey serum samples investigated in 
this study.
Age and breeding history are speculated to be risk factors asso-
ciated with EqPV- H infection, while seasonal occurrence of EqPV- 
H- associated cases of clinical hepatitis has been reported 4,6,11. 
Our findings have identified a significantly higher chance of active 
EqPV- H infection in 16- to 31- year- old horses, compared with 1- to 
8- year- old horses, as well as 9- to 15- year- old horses. With every 
increase of 1 year in age, the risk of active EqPV- H infection is 1.1 
times higher. The risk becomes increasingly greater with increasing 
age, culminating in the highest risk in horses of advanced age. Future 
investigations into the horizontal routes of EqPV- H transmission 
and immunological response mechanisms underlying ongoing infec-
tions versus viral clearance may help to explain the observed age 
predilection.
Clinical disease, ranging in severity from acute, fatal hepatitis 
to subclinical infection, has been reported in horses with active 
EqPV- H infection.1,3– 8 Considering the varying severity of associ-
ated clinical signs and previous reports of normal liver- associated 
biochemistry parameters in EqPV- H DNA- positive horses, it is not 
surprising that the parameters investigated in this group of horses 
with active EqPV- H infection did not differ significantly from the 
TA B L E  4   Specifications of the liver- associated biochemistry parameters glutamate dehydrogenase (GLDH), gamma- glutamyl transferase 
(GGT), bile acids and albumin measured in plasma samples of all horses with active EqPV- H infection ([Ab+/DNA+] + [Ab−/DNA+]) (n = 23), 











EqPV- H DNA status Positive Negative Positive Negative Positive Negative Positive Negative
n 23 45 23 45 23 45 23 45
Range (min – max) 1.6 – 5.5 1.4 – 42.5 5 – 37 1 – 42 2 – 10 2 – 11 2.5 – 4.1 2 – 4.4
Interquartile range 2.2 – 4.2 2.2 – 4.2 8 - 18 9 - 15 3 - 7 4 – 6.5 3 – 3.2 2.7 – 3.4
Median 2.8 2.8 13 12 5 5 3.1 3
Normal distribution No No No No Yes No No Yes
Nonparametric test The Mann- Whitney U The Mann- Whitney U The Mann- Whitney U The Mann- Whitney U
P- value P = .9 P = .6 P = .3 P = .2
Note: P ≤ .05 was considered statistically significant.
F I G U R E  5   Liver- associated 
biochemistry parameters glutamate 
dehydrogenase (GLDH, reference < 13 
U/L), gamma- glutamyl transferase 
(GGT, reference < 30 U/L), bile acids 
(reference < 20 µmol/L) and albumin 
(reference 2.4- 4.5 g/dL) measured in 
plasma samples of all horses with active 
EqPV- H infection ([Ab+/DNA+] + [Ab−/
DNA+]) (n = 23), as well as control horses 
(n = 45). All control horses were known to 
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control group. Although published data have left very little doubt 
about the matter, it should be noted that in the case of EqPV- H, 
disease causation has not been confirmed. A pure, clonal, EqPV- H 
inoculum is still required to definitively confirm that EqPV- H can be 
a cause of liver disease.
With the exception of a single recombination event reported 
between Chinese and American EqPV- H strains,8 low genetic di-
versity has been reported among EqPV- H variants identified glob-
ally.1,5,8,9,11,14 In accordance with these findings, sequencing and 
phylogenetic analyses of NS1 coding sequences and complete CDS 
of Austrian EqPV- H variants revealed minor overall differences at 
nucleotide level and high similarity to published sequences from 
Germany, Italy and China.
Limitations of the study include the inclusion criteria of 
equids in the study population, which were entirely dependent 
upon owner consent. There was only a single sampling point 
per animal. Longitudinal monitoring, favouring the detection 
of short- term changes in liver- associated biochemistry param-
eters, has been previously recommended in cases of EqHV.18 
This approach could also be beneficial for detecting biochemis-
try changes associated with EqPV- H infection. Due to the small 
sample size, little conclusion could be drawn regarding EqPV- H 
infection in donkeys.
5  | CONCLUSION
EqPV- H antibodies and DNA are frequently detected in Austrian 
horses, without associated hepatitis in horses with active infection. 
The risk of active EqPV- H infection increases with increasing age. 
F I G U R E  6   Molecular phylogenetic 
analysis of NS1 PCR products by 
maximum likelihood method. The 
maximum likelihood phylogenetic tree 
is drawn to scale, with branch lengths 
measured in the number of substitutions 
per site. All positions containing gaps and 
missing data were eliminated, resulting in 
a total of 478 positions in the final dataset. 
Evolutionary analyses were conducted in 
MEGA7. The human parvovirus sequence 
B19 (NC_000883.2) was used as 
outgroup. Due to low similarity to EqPV- H 
and for visualisation purposes, this branch 
was trimmed as indicated by dashed 
lines. Sequences of Austrian horses are 
indicated with black circles. Accession 
number and the country of sample origin 
identify previously published EqPV- H 
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Phylogenetic evidence supports the close relation of EqPV- H vari-
ants circulating globally, including variants in Austria.
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